Genprex, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 1.48%139.510.7%$2230.13m
PFEPfizer Inc. 1.07%33.970.9%$1409.12m
MRKMerck & Co., Inc. 1.69%79.890.7%$1315.50m
ABBVAbbVie, Inc. 1.90%76.822.3%$1231.67m
BMYBristol-Myers Squibb Co. 1.14%57.551.0%$1151.07m
LLYEli Lilly & Co. 1.18%143.561.1%$871.88m
NVSNovartis AG 1.43%85.190.2%$297.87m
AZNAstraZeneca Plc 0.88%43.481.2%$293.60m
GSKGlaxoSmithKline Plc 0.84%37.850.2%$253.20m
NVONovo Nordisk A/S 1.49%59.410.1%$171.03m
SNYSanofi 0.14%44.660.2%$169.85m
FTSVForty Seven, Inc. 0.05%95.510.0%$145.52m
BHCBausch Health Cos., Inc. 3.17%15.320.0%$102.80m
RGENRepligen Corp. -1.98%94.747.1%$68.11m
RETAReata Pharmaceuticals, Inc. 1.66%136.883.4%$64.89m

Company Profile

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.